Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
Idiopathic pulmonary arterial hypertension (IPAH) is a complex disease associated with progressive deterioration. Targeted therapy for IPAH has improved in the last several decades. However, there remain many challenges to current treatment of children with IPAH, including poor prognosis and a media...
Saved in:
Main Authors: | Yuchen Wang (Author), Selena Chen (Author), Junbao Du (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
by: Kari E Roberts, et al.
Published: (2009) -
Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
by: Pierangelo Chinello, et al.
Published: (2011) -
Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
by: Tomas Jasenovec, et al.
Published: (2022) -
Orthostatic Hypertension in Children: An Update
by: Yang Hu, et al.
Published: (2020) -
Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases
by: M. Rizzo, et al.
Published: (2011)